Cargando…
Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study
Inhibition of angiotensin II synthesis seems to decrease hepatocellular carcinoma recurrence after radical therapies; however, data on the adjuvant role of angiotensin II receptor 1 blockers (sartans) are still lacking. Aim of the study was to evaluate whether sartans delay time to recurrence and pr...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599746/ https://www.ncbi.nlm.nih.gov/pubmed/33050084 http://dx.doi.org/10.3390/biomedicines8100399 |
_version_ | 1783602955471028224 |
---|---|
author | Facciorusso, Antonio Abd El Aziz, Mohamed A. Cincione, Ivan Cea, Ugo Vittorio Germini, Alessandro Granieri, Stefano Cotsoglou, Christian Sacco, Rodolfo |
author_facet | Facciorusso, Antonio Abd El Aziz, Mohamed A. Cincione, Ivan Cea, Ugo Vittorio Germini, Alessandro Granieri, Stefano Cotsoglou, Christian Sacco, Rodolfo |
author_sort | Facciorusso, Antonio |
collection | PubMed |
description | Inhibition of angiotensin II synthesis seems to decrease hepatocellular carcinoma recurrence after radical therapies; however, data on the adjuvant role of angiotensin II receptor 1 blockers (sartans) are still lacking. Aim of the study was to evaluate whether sartans delay time to recurrence and prolong overall survival in hepatocellular carcinoma patients after radiofrequency ablation. Data on 215 patients were reviewed. The study population was classified into three groups: 113 (52.5%) patients who received neither angiotensin-converting enzyme inhibitors nor sartans (group 1), 59 (27.4%) patients treated with angiotensin-converting enzyme inhibitors (group 2) and 43 (20.1%) patients treated with sartans (group 3). Survival outcomes were analyzed using Kaplan–Meier analysis and compared with log-rank test. In the whole study population, 85.6% of patients were in Child-Pugh A-class and 89.6% in Barcelona Clinic Liver Cancer A stage. Median maximum tumor diameter was 30 mm (10–40 mm) and alpha-fetoprotein was 25 (1.1–2100) IU/mL. No differences in baseline characteristics among the three groups were reported. Median overall survival was 48 months (42–51) in group 1, 51 months (42–88) in group 2, and 63 months (51–84) in group 3 (p = 0.15). Child-Pugh stage and Model for End-staging Liver Disease (MELD) score resulted as significant predictors of overall survival in multivariate analysis. Median time to recurrence was 33 months (24–35) in group 1, 41 (23–72) in group 2 and 51 months (42–88) in group 3 (p = 0.001). Number of nodules and anti-angiotensin treatment were confirmed as significant predictors of time to recurrence in multivariate analysis. Sartans significantly improved time to recurrence after radiofrequency ablation in hepatocellular carcinoma patients but did not improve overall survival. |
format | Online Article Text |
id | pubmed-7599746 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-75997462020-11-01 Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study Facciorusso, Antonio Abd El Aziz, Mohamed A. Cincione, Ivan Cea, Ugo Vittorio Germini, Alessandro Granieri, Stefano Cotsoglou, Christian Sacco, Rodolfo Biomedicines Article Inhibition of angiotensin II synthesis seems to decrease hepatocellular carcinoma recurrence after radical therapies; however, data on the adjuvant role of angiotensin II receptor 1 blockers (sartans) are still lacking. Aim of the study was to evaluate whether sartans delay time to recurrence and prolong overall survival in hepatocellular carcinoma patients after radiofrequency ablation. Data on 215 patients were reviewed. The study population was classified into three groups: 113 (52.5%) patients who received neither angiotensin-converting enzyme inhibitors nor sartans (group 1), 59 (27.4%) patients treated with angiotensin-converting enzyme inhibitors (group 2) and 43 (20.1%) patients treated with sartans (group 3). Survival outcomes were analyzed using Kaplan–Meier analysis and compared with log-rank test. In the whole study population, 85.6% of patients were in Child-Pugh A-class and 89.6% in Barcelona Clinic Liver Cancer A stage. Median maximum tumor diameter was 30 mm (10–40 mm) and alpha-fetoprotein was 25 (1.1–2100) IU/mL. No differences in baseline characteristics among the three groups were reported. Median overall survival was 48 months (42–51) in group 1, 51 months (42–88) in group 2, and 63 months (51–84) in group 3 (p = 0.15). Child-Pugh stage and Model for End-staging Liver Disease (MELD) score resulted as significant predictors of overall survival in multivariate analysis. Median time to recurrence was 33 months (24–35) in group 1, 41 (23–72) in group 2 and 51 months (42–88) in group 3 (p = 0.001). Number of nodules and anti-angiotensin treatment were confirmed as significant predictors of time to recurrence in multivariate analysis. Sartans significantly improved time to recurrence after radiofrequency ablation in hepatocellular carcinoma patients but did not improve overall survival. MDPI 2020-10-08 /pmc/articles/PMC7599746/ /pubmed/33050084 http://dx.doi.org/10.3390/biomedicines8100399 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Facciorusso, Antonio Abd El Aziz, Mohamed A. Cincione, Ivan Cea, Ugo Vittorio Germini, Alessandro Granieri, Stefano Cotsoglou, Christian Sacco, Rodolfo Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study |
title | Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study |
title_full | Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study |
title_fullStr | Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study |
title_full_unstemmed | Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study |
title_short | Angiotensin Receptor 1 Blockers Prolong Time to Recurrence after Radiofrequency Ablation in Hepatocellular Carcinoma patients: A Retrospective Study |
title_sort | angiotensin receptor 1 blockers prolong time to recurrence after radiofrequency ablation in hepatocellular carcinoma patients: a retrospective study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7599746/ https://www.ncbi.nlm.nih.gov/pubmed/33050084 http://dx.doi.org/10.3390/biomedicines8100399 |
work_keys_str_mv | AT facciorussoantonio angiotensinreceptor1blockersprolongtimetorecurrenceafterradiofrequencyablationinhepatocellularcarcinomapatientsaretrospectivestudy AT abdelazizmohameda angiotensinreceptor1blockersprolongtimetorecurrenceafterradiofrequencyablationinhepatocellularcarcinomapatientsaretrospectivestudy AT cincioneivan angiotensinreceptor1blockersprolongtimetorecurrenceafterradiofrequencyablationinhepatocellularcarcinomapatientsaretrospectivestudy AT ceaugovittorio angiotensinreceptor1blockersprolongtimetorecurrenceafterradiofrequencyablationinhepatocellularcarcinomapatientsaretrospectivestudy AT germinialessandro angiotensinreceptor1blockersprolongtimetorecurrenceafterradiofrequencyablationinhepatocellularcarcinomapatientsaretrospectivestudy AT granieristefano angiotensinreceptor1blockersprolongtimetorecurrenceafterradiofrequencyablationinhepatocellularcarcinomapatientsaretrospectivestudy AT cotsoglouchristian angiotensinreceptor1blockersprolongtimetorecurrenceafterradiofrequencyablationinhepatocellularcarcinomapatientsaretrospectivestudy AT saccorodolfo angiotensinreceptor1blockersprolongtimetorecurrenceafterradiofrequencyablationinhepatocellularcarcinomapatientsaretrospectivestudy |